RT Journal Article SR Electronic T1 Susceptibility vessel sign on MRI predicts better clinical outcome in patients with anterior circulation acute stroke treated with stent retriever as first-line strategy JF Journal of NeuroInterventional Surgery JO J NeuroIntervent Surg FD BMJ Publishing Group Ltd. SP 328 OP 333 DO 10.1136/neurintsurg-2018-014217 VO 11 IS 4 A1 Bourcier, Romain A1 Hassen, Wagih Ben A1 Soize, Sébastien A1 Roux, Pascal A1 Labreuche, Julien A1 Kyheng, Maeva A1 Tisserand, Marie A1 Rosso, Charlotte A1 Blanc, Raphael A1 Piotin, Michel A1 Derraz, Imad A1 Boulouis, Gregoire A1 Oppenheim, Catherine A1 Desal, Hubert A1 Bracard, Serge A1 Lapergue, Bertrand A1 Naggara, Olivier A1 YR 2019 UL http://jnis.bmj.com/content/11/4/328.abstract AB Background Susceptibility vessel sign (SVS) can be a useful MRI biomarker of an occlusion but its relationship with clinical outcomes of acute ischemic stroke (AIS) is yet to be fully elucidated.Objective To investigate SVS in relation to the clinical outcomes after mechanical thrombectomy using a stent retriever (SR) as first-line approach in patients with AIS.Material and methods We included patients with a first-line SR approach for anterior AIS from the the Contact Aspiration vs Stent Retriever for Successful Revascularization (ASTER) and THRombectomie des Artères CErebrales (THRACE) trials when both baseline imaging of SVS and 90-day modified Rankin Scale (mRS) scores were available. Patients were assigned to two groups based on the presence of an SVS (independent core laboratory), and the overall distributions of the mRS score at 90 days (shift analysis) and clinical independence (mRS score ≤2) were compared.Results 217 patients were included and SVS was diagnosed in 76.0% of cases (n=165, 95% CI 70.4% to 81.7%). After adjustment for potential confounders, SVS+ was significantly associated with 90-day mRS improvement (adjusted common OR=2.75; 95% CI 1.44 to 5.26) and favorable outcome (adjusted common OR=2.76; 95% CI 1.18 to 6.45).Conclusion Based on results for patients of the ASTER and THRACE trials receiving first-line SR treatment, SVS was associated with lower disability at 3 months. Large prospective studies using MRI-based thrombus evaluation are warranted.